Pharmaceutical Executive
As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development.
Clara Heering
Advertisement
Articles by Clara Heering
Advertisement
Latest Updated Articles
What Errors Do We Miss in Clinical Trials?March 8th 2016
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
The Evolving Relationship Between FDA and Biotech
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5